相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Phase II Study of Bevacizumab and Everolimus as Treatment for Refractory Metastatic Renal Cell Carcinoma
Lauren C. Harshman et al.
CLINICAL GENITOURINARY CANCER (2013)
A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
D. S. Boss et al.
BRITISH JOURNAL OF CANCER (2012)
Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma
In-Chang Cho et al.
KOREAN JOURNAL OF UROLOGY (2012)
Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies
M. E. Gore et al.
BRITISH JOURNAL OF CANCER (2011)
A Phase 1 Study of Everolimus and Sorafenib for Metastatic Clear Cell Renal Cell Carcinoma
Andrea L. Harzstark et al.
CANCER (2011)
Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors
Kazuhiko Yamada et al.
CLINICAL CANCER RESEARCH (2011)
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini et al.
LANCET (2011)
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial
Sylvie Negrier et al.
LANCET ONCOLOGY (2011)
Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Clinical Evidence
Thomas E. Hutson
ONCOLOGIST (2011)
Combination Therapy for Renal Cell Cancer: What Are Possible Options?
Napoleon Santos et al.
ONCOLOGY (2011)
Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors
Robert J. Motzer et al.
CANCER (2010)
Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma
John D. Hainsworth et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Diagnostic and Prognostic Molecular Markers for Renal Cell Carcinoma: A Critical Appraisal of the Current State of Research and Clinical Applicability
Christian Eichelberg et al.
EUROPEAN UROLOGY (2009)
Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Darren R. Feldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Resistance to targeted therapy in renal-cell carcinoma
Brian I. Rini et al.
LANCET ONCOLOGY (2009)
E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition
Junji Matsui et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Opportunities and obstacles to combination targeted therapy in renal cell cancer
Jeffrey A. Sosman et al.
CLINICAL CANCER RESEARCH (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib in patients with metastatic renal cell carcinoma
Robert J. Motzer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
GV Thomas et al.
NATURE MEDICINE (2006)
The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing
WG Kaelin
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Targeted agents for the treatment of advanced renal cell carcinoma
M Staehler et al.
CURRENT DRUG TARGETS (2005)
A small molecule-kinase interaction map for clinical kinase inhibitors
MA Fabian et al.
NATURE BIOTECHNOLOGY (2005)
TSC2 regulates VEGF through mTOR-dependent and -independent pathways
JB Brugarolas et al.
CANCER CELL (2003)
分享论文
